News
-
-
PRESS RELEASE
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals presents statistically significant results of crofelemer in breast cancer patients for prophylaxis of CTD at SABCS. Study highlights impact of diarrhea in cancer treatment -
-
PRESS RELEASE
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Jaguar Health's Napo Pharmaceuticals to present data on crofelemer in breast cancer patients at SABCS 2024. Additional analyses ongoing. Patient advocacy program also announced -
-
PRESS RELEASE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Jaguar Health's crofelemer undergoing clinical studies for rare diseases SBS-IF and MVID in multiple regions; Orphan Drug Designation granted by FDA and EMA -
-
PRESS RELEASE
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
Jaguar Health announces Canalevia-CA1, a canine-specific crofelemer drug for chemotherapy-induced diarrhea in dogs with FDA approval, detailed safety information provided -
-
PRESS RELEASE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Inc. announces extension of conditional approval by FDA for Canalevia®-CA1 drug for chemotherapy-induced diarrhea in dogs and seeks partners for NP300 prescription drug for general diarrhea in dogs at Pet Connect conference
